Related Experiment Video
Updated: Sep 24, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Molecular Imaging of Renal Cell Carcinoma in Precision Medicine
Qianyun Wu1, Gang Huang1, Weijun Wei1
1Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200217, China.
Abstract:
Renal cell carcinoma (RCC) is the sixth most common cancer among men and the ninth among women, and its prognosis is closely correlated with metastasis. Targeted therapy and immunotherapy are the main adjuvant treatments for advanced RCC and require early diagnosis, precise assessment, and prediction of the therapeutic responses. Current conventional imaging methods of RCC only provide structural information rather than biological processes. Noninvasive diagnostic tools are therefore needed to image RCC early and accurately at the molecular level. Nuclear medicine imaging combines the high sensitivity of radionuclides with the high resolution of structural imaging to visualize the metabolic processes and specific targets of RCC for more accurate and reliable diagnosis, staging, prognosis prediction, and response assessment. This review summarizes the most recent applications of nuclear medicine receptor imaging and metabolic imaging in RCC and highlights future development perspectives in the field.
Insights
Nuclear medicine imaging offers advanced, noninvasive tools for early renal cell carcinoma (RCC) diagnosis and treatment monitoring. This review explores its role in receptor and metabolic imaging for better patient outcomes.
Area of Science:
- Oncology
- Radiology
- Nuclear Medicine
Background:
- Renal cell carcinoma (RCC) is a significant global cancer with prognosis tied to metastasis.
- Advanced RCC treatments require early diagnosis, precise assessment, and prediction of therapeutic responses.
- Conventional imaging lacks molecular-level insights into RCC's biological processes.
Purpose of the Study:
- To review recent advances in nuclear medicine imaging for renal cell carcinoma (RCC).
- To highlight the application of receptor and metabolic imaging in RCC diagnosis and management.
- To discuss future perspectives for nuclear medicine in RCC detection and treatment.
Main Methods:
- Review of current literature on nuclear medicine imaging techniques in RCC.
- Focus on receptor imaging and metabolic imaging applications.
- Analysis of diagnostic, prognostic, and therapeutic response assessment capabilities.
Main Results:
- Nuclear medicine imaging provides sensitive, molecular-level insights into RCC.
- Receptor and metabolic imaging aid in early diagnosis, staging, and prognosis prediction.
- These techniques are crucial for assessing responses to targeted therapy and immunotherapy.
Conclusions:
- Nuclear medicine imaging is vital for noninvasive, accurate, and early assessment of renal cell carcinoma.
- It enhances diagnosis, staging, prognosis, and treatment response prediction in advanced RCC.
- Future developments promise further improvements in personalized RCC management through nuclear medicine.
More Related Videos
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017